apoe deficient mouse
Recently Published Documents


TOTAL DOCUMENTS

28
(FIVE YEARS 0)

H-INDEX

14
(FIVE YEARS 0)

2018 ◽  
Vol 115 (1) ◽  
pp. 190-203 ◽  
Author(s):  
Xin Sun ◽  
Shuyuan Guo ◽  
Jianting Yao ◽  
Huan Wang ◽  
Chenghai Peng ◽  
...  

Abstract Aims Currently, efficient regimens to reverse atherosclerotic plaques are not available in the clinic. Herein, we present sonodynamic therapy (SDT) as a novel methodology to rapidly inhibit progression of atherosclerotic plaques. Methods and results In atherosclerotic rabbit and apoE-deficient mouse models, SDT efficiently decreased the atherosclerotic burden within 1 week, revealing a decrease in the size of the atherosclerotic plaque and enlarged lumen. The shrunken atherosclerotic plaques displayed compositional alterations, with a reduction in lesional macrophages and lipids. The rapid efficacy of SDT may be due to its induction of macrophage apoptosis, enhancement of efferocytosis, and amelioration of inflammation in the atherosclerotic plaque. Compared with atorvastatin, the standard of care for atherosclerosis, SDT showed more significant plaque shrinkage and lumen enlargement during 1 week treatment. Furthermore, SDT displayed good safety without obvious side effects. In a pilot clinical trial recruiting the patients suffering atherosclerotic peripheral artery disease, combination therapy of SDT with atorvastatin efficiently reduced progression of atherosclerotic plaque within 4 weeks, and its efficacy was able to last for at least 40 weeks. Conclusion SDT is a non-invasive and efficacious regimen to inhibit atherosclerotic plaque progression.


In Vivo ◽  
2018 ◽  
Vol 32 (5) ◽  
pp. 1025-1032 ◽  
Author(s):  
HONG YUAN ◽  
HAIQIANG HU ◽  
JINDONG SUN ◽  
MINGJUAN SHI ◽  
HUAMIN YU ◽  
...  

2017 ◽  
Vol 26 (2) ◽  
pp. 385-393 ◽  
Author(s):  
Jinxia Han ◽  
Dongwei Chen ◽  
Dayi Liu ◽  
Yanan Zhu

BMC Genetics ◽  
2015 ◽  
Vol 16 (1) ◽  
Author(s):  
Qian Wang ◽  
Andrew T. Grainger ◽  
Ani Manichaikul ◽  
Emily Farber ◽  
Suna Onengut-Gumuscu ◽  
...  

2015 ◽  
Vol 70 (2) ◽  
pp. 113-118 ◽  
Author(s):  
Juliane Radtke ◽  
Alexandra Schutkowski ◽  
Corinna Brandsch ◽  
Frank Hirche ◽  
Katrin Hasenkopf ◽  
...  

2015 ◽  
Vol 159 ◽  
pp. 84-92 ◽  
Author(s):  
Minqi Xiong ◽  
Chenglin Jia ◽  
Jingang Cui ◽  
Peiwei Wang ◽  
Xiaoye Du ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e99849 ◽  
Author(s):  
Chenglin Jia ◽  
Minqi Xiong ◽  
Peiwei Wang ◽  
Jingang Cui ◽  
Xiaoye Du ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Tomoko Kurita-Ochiai ◽  
Masafumi Yamamoto

Inflammation is well accepted to play a crucial role in the development of atherosclerotic lesions, and recent studies have demonstrated an association between periodontal disease and cardiovascular disease.Porphyromonas gingivalisandAggregatibacter actinomycetemcomitans, causative agents of destructive chronic inflammation in the periodontium, can accelerate atheroma deposition in animal models. Emerging evidence suggests that vaccination against virulence factors of these pathogens and anti-inflammatory therapy may confer disease resistance. In this review, we focus on the role of inflammatory mechanisms and oxidative modification in the formation and activation of atherosclerotic plaques accelerated byP. gingivalisorA. actinomycetemcomitansin an ApoE-deficient mouse model and high-fat-diet-fed mice. Furthermore, we examine whether mucosal vaccination with a periodontal pathogen or the anti-inflammatory activity of catechins can reduce periodontal pathogen-accelerated atherosclerosis.


2013 ◽  
Vol 7 (11-12) ◽  
pp. 829-838 ◽  
Author(s):  
Xiaoyan Lv ◽  
Jianzhong Ai ◽  
Mi Li ◽  
Honglian Wang ◽  
Tielin Chen ◽  
...  

2011 ◽  
pp. P1-597-P1-597
Author(s):  
Nyosha Alikhani ◽  
Rulan Novosyadlyy ◽  
Rosalyn Ferguson ◽  
Shoshana Yakar ◽  
Derek LeRoith

Sign in / Sign up

Export Citation Format

Share Document